{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:37:26Z","timestamp":1793385446505,"version":"4.5.0"},"reference-count":39,"publisher":"BMJ","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2013,6,14]]},"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Clarithromycin strongly inhibits enzyme cytochrome P450 3A4, preventing the metabolism of some other drugs, while azithromycin is a weak inhibitor. Accordingly, blood concentrations of other drugs increase with clarithromycin coprescription leading to adverse events. These macrolide antibiotics also differ on other properties that may impact outcomes. In this study, we compared outcomes in two groups of macrolide antibiotic users in the absence of potentially interacting drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Population-based retrospective cohort study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Ontario, Canada, from 2003 to 2010.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Patients (mean 74\u2005years) prescribed clarithromycin (n=52\u2005251) or azithromycin (referent group, n=46\u2005618).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcomes<\/jats:title><jats:p>The primary outcomes were hospital admission within 30\u2005days of a new antibiotic prescription with any of the 12 conditions examined separately (acute kidney injury, acute myocardial infarction, neuroimaging (proxy for delirium), hypotension, syncope, hyperkalaemia, hyponatraemia, hyperglycaemia, arrhythmia, ischaemic stroke, gastrointestinal bleeding and sepsis). The secondary outcome was mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The baseline characteristics of the two groups, including patient demographics, comorbid conditions, infection type and prescribing physician specialty, were nearly identical. The median daily dose was 1000\u2005mg for clarithromycin and 300\u2005mg for azithromycin and the median duration of dispensing antibiotics was 10 and 5\u2005days, respectively. There was no difference between the groups in the risk of hospitalisation for any condition studied (relative risk ranged from 0.67 to 1.23). Compared with azithromycin, clarithromycin was associated with a slightly higher risk of all-cause mortality (0.46% vs 0.37%, relative risk 1.25, 95% CI 1.03 to 1.52).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Clarithromycin can be used to assess drug interactions in population-based studies with azithromycin serving as a control group. However, any differences in mortality observed between the two antibiotic groups in the setting of other drug use may be partially attributable to factors beyond the inhibition of drug metabolising enzymes and transporters, as the difference for this outcome was significant.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2013-002857","type":"journal-article","created":{"date-parts":[[2013,7,12]],"date-time":"2013-07-12T04:23:24Z","timestamp":1373603004000},"page":"e002857","source":"Crossref","is-referenced-by-count":21,"title":["Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions"],"prefix":"10.1136","volume":"3","author":[{"given":"Jamie L","family":"Fleet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salimah Z","family":"Shariff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N","family":"Juurlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Mamdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit X","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,7,11]]},"reference":[{"key":"2024051504413871000_3.7.e002857.1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200038010-00003"},{"key":"2024051504413871000_3.7.e002857.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032424"},{"key":"2024051504413871000_3.7.e002857.3","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.120951"},{"key":"2024051504413871000_3.7.e002857.4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2165\/11599090-000000000-00000","article-title":"Use of clarithromycin and adverse cardiovascular events among older patients receiving donepezil: a population-based, nested case-control study","volume":"29","author":"Hutson","year":"2012","journal-title":"Drugs Aging"},{"key":"2024051504413871000_3.7.e002857.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.09.003"},{"key":"2024051504413871000_3.7.e002857.6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1006\/phrs.2002.0957","article-title":"Factors contributing to carbamazepine-macrolide interactions","volume":"45","author":"Pauwels","year":"2002","journal-title":"Pharmacol Res"},{"key":"2024051504413871000_3.7.e002857.7","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.014407"},{"key":"2024051504413871000_3.7.e002857.8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00261.x"},{"key":"2024051504413871000_3.7.e002857.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0091-x"},{"key":"2024051504413871000_3.7.e002857.10","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-12-201306180-00004"},{"key":"2024051504413871000_3.7.e002857.11","unstructured":"Clarithromycin Drug Information. UptoDate online V 20.3. 2012. 5-25-0120. Ref Type: Electronic Citation"},{"key":"2024051504413871000_3.7.e002857.12","unstructured":"Azithromycin Drug Information. UptoDate online V 20.3. 2012. 5-25-0120. Ref Type: Electronic Citation"},{"key":"2024051504413871000_3.7.e002857.13","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181bbbcd7"},{"key":"2024051504413871000_3.7.e002857.14","first-page":"283","article-title":"Clarithromycin-induced rhabdomyolysis: a case report","volume":"5","author":"Pasqualetti","year":"2012","journal-title":"Int J Gen Med"},{"key":"2024051504413871000_3.7.e002857.15","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.100702"},{"key":"2024051504413871000_3.7.e002857.16","unstructured":"Statistics Canada. Population by sex and age group, by province and territory. Ottawa: Statistics Canada, 2011; 8-10-0120. Ref Type: Electronic Citation"},{"key":"2024051504413871000_3.7.e002857.17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"2024051504413871000_3.7.e002857.18","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database","volume":"10","author":"Levy","year":"2003","journal-title":"Can J Clin Pharmacol"},{"key":"2024051504413871000_3.7.e002857.19","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.18"},{"key":"2024051504413871000_3.7.e002857.20","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.227"},{"key":"2024051504413871000_3.7.e002857.21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-156-8-201204170-00401","article-title":"New fibrate use and acute renal outcomes in elderly adults: a population-based study","volume":"156","author":"Zhao","year":"2012","journal-title":"Ann Intern Med"},{"key":"2024051504413871000_3.7.e002857.22","unstructured":"Flockhart DA . Drug interactions: cytochrome P450 drug interaction table. India. 2012. Ref Type: Electronic Citation"},{"key":"2024051504413871000_3.7.e002857.23","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.002857"},{"key":"2024051504413871000_3.7.e002857.24","first-page":"182","article-title":"Calcium channel blockers+macrolides: elderly patients hospitalised for low blood pressure","volume":"21","year":"2012","journal-title":"Prescrire Int"},{"key":"2024051504413871000_3.7.e002857.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2010.02.013"},{"key":"2024051504413871000_3.7.e002857.26","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.cjca.2011.06.006","article-title":"Digoxin toxicity precipitated by clarithromycin use: case presentation and concise review of the literature","volume":"27","author":"Lee","year":"2011","journal-title":"Can J Cardiol"},{"key":"2024051504413871000_3.7.e002857.27","doi-asserted-by":"publisher","DOI":"10.1097\/00003072-200412000-00008"},{"key":"2024051504413871000_3.7.e002857.28","doi-asserted-by":"publisher","DOI":"10.4103\/0972-5229.84901"},{"key":"2024051504413871000_3.7.e002857.29","doi-asserted-by":"publisher","DOI":"10.1080\/03610910902859574"},{"key":"2024051504413871000_3.7.e002857.30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7497.960"},{"key":"2024051504413871000_3.7.e002857.31","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2024051504413871000_3.7.e002857.32","first-page":"31","article-title":"The new macrolides. Azithromycin and clarithromycin","volume":"160","author":"Kanatani","year":"1994","journal-title":"West J Med"},{"key":"2024051504413871000_3.7.e002857.33","doi-asserted-by":"publisher","DOI":"10.1016\/0195-6701(91)90215-T"},{"key":"2024051504413871000_3.7.e002857.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90837-8"},{"key":"2024051504413871000_3.7.e002857.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040582"},{"key":"2024051504413871000_3.7.e002857.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003833"},{"key":"2024051504413871000_3.7.e002857.37","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932020-00008"},{"key":"2024051504413871000_3.7.e002857.38","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_E.153"},{"key":"2024051504413871000_3.7.e002857.39","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_E.137"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2013-002857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T15:41:36Z","timestamp":1715787696000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2013-002857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1136\/bmjopen-2013-002857"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2013-002857","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}